<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">1463</journal-id><journal-id journal-id-type="pmc-domain">frontpsychiat</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10509760</article-id><article-id pub-id-type="pmcid-ver">PMC10509760.1</article-id><article-id pub-id-type="pmcaid">10509760</article-id><article-id pub-id-type="pmcaiid">10509760</article-id><article-id pub-id-type="pmid">37736060</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2023.1251955</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Search for serum biomarkers in patients with bipolar disorder and major depressive disorder using metabolome analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Sun</surname><given-names initials="XL">Xiao-Li</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Ma</surname><given-names initials="LN">Li-Na</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="ZZ">Zhen-Zhu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names initials="YB">Yan-Bing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/692961/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jia</surname><given-names initials="J">Jiao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yu</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ren</surname><given-names initials="Y">Yan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/996818/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Psychiatry, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Changzhi Mental Health Center</institution>, <addr-line>Changzhi</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Hikaru Hori, Fukuoka University, Japan</p></fn><fn fn-type="edited-by"><p>Reviewed by: Mariusz Stanis&#322;aw Wiglusz, Medical University of Gda&#324;sk, Poland; Jun-sheng Tian, Shanxi University, China</p></fn><corresp id="c001">*Correspondence: Yan Ren, <email>renyansxmu@outlook.com</email></corresp><fn fn-type="equal" id="fn002"><p><sup>&#8224;</sup>These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427509</issue-id><elocation-id>1251955</elocation-id><history><date date-type="received"><day>03</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>21</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-09-22 11:25:09.683"><day>22</day><month>09</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Sun, Ma, Chen, Xiong, Jia, Wang and Ren.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Sun, Ma, Chen, Xiong, Jia, Wang and Ren</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fpsyt-14-1251955.pdf"/><abstract><sec><title>Objective</title><p>Bipolar disorder (BD) and major depressive disorder (MDD) are two common psychiatric disorders. Due to the overlapping clinical symptoms and the lack of objective diagnostic biomarkers, bipolar disorder (BD) is easily misdiagnosed as major depressive disorder (MDD), which in turn affects treatment decisions and prognosis. This study aimed to investigate biomarkers that could be used to differentiate BD from MDD.</p></sec><sec><title>Methods</title><p>Nuclear magnetic resonance (NMR) spectroscopy was performed to assess serum metabolic profiles in depressed patients with BD (<italic toggle="yes">n</italic> = 59), patients with MDD (<italic toggle="yes">n</italic> = 14), and healthy controls (<italic toggle="yes">n</italic> = 10). Data was analyzed using partial least squares discriminant analysis, orthogonal partial least squares discriminant analysis and <italic toggle="yes">t</italic>-tests. Different metabolites (VIP &gt; 1 and <italic toggle="yes">p</italic> &lt; 0.05) were identified and further analyzed using Metabo Analyst 5.0 to identify relevant metabolic pathways.</p></sec><sec><title>Results</title><p>The metabolic phenotypes of the BD and MDD groups were significantly different from those of the healthy controls, and there were different metabolite differences between them. In the BD group, the levels of 3-hydroxybutyric acid, n-acetyl glycoprotein, &#946;-glucose, pantothenic acid, mannose, glycerol, and lipids were significantly higher than those in the healthy control group, and the levels of lactate and acetoacetate were significantly lower than those in the healthy control group. In the MDD group, the levels of 3-hydroxybutyric acid, n-acetyl glycoprotein, pyruvate, choline, acetoacetic acid, and lipids were significantly higher than those of healthy controls, and the levels of acetic acid and glycerol were significantly lower than those of healthy controls.</p></sec><sec><title>Conclusion</title><p>Glycerolipid metabolism is significantly involved in BD and MDD. Pyruvate metabolism is significantly involved in MDD. Pyruvate, choline, and acetate may be potential biomarkers for MDD to distinguish from BD, and pantothenic acid may be a potential biomarker for BD to distinguish from MDD.</p></sec></abstract><kwd-group><kwd>bipolar disorder</kwd><kwd>major depressive disorder</kwd><kwd>metabonomics</kwd><kwd>biomarker</kwd><kwd>nuclear magnetic resonance</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">8210053813</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Shanxi Scholarship Council of China</institution><institution-id institution-id-type="doi">10.13039/501100003398</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn002">2021-167</award-id></award-group></funding-group><funding-group><funding-statement>This work was supported by the National Natural Science Foundation of China (8210053813), Applied Basic Research Projects of Shanxi Province, China (201901D111418), and the Research Project Supported by Shanxi Scholarship Council of China (2021-167).</funding-statement></funding-group><counts><fig-count count="10"/><table-count count="4"/><equation-count count="0"/><ref-count count="52"/><page-count count="12"/><word-count count="7137"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Mood Disorders</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>1. Introduction</title><p>Major depressive disorder (MDD) and bipolar disorder (BD) are two different psychiatric disorders with commonly overlapping symptoms. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), MDD is characterized by the presence of major depressive episodes, whereas patients with BD have depressive episodes preceding or following a mild manic or manic episode [American Psychiatric Association (<xref rid="B1" ref-type="bibr">1</xref>)]. Typically, patients with BD cycle between manic, depressive, and normal mood episodes; however, the depressive phase of BD occurs more frequently than the hypomanic or manic phase (<xref rid="B2" ref-type="bibr">2</xref>); BD I is characterized by one or more manic episodes or mixed episodes and major depressive episodes; BD II is characterized by recurrent depressive episodes and hypomanic episodes, but no manic episodes; but hypomania is in fact difficult to detect in clinical practice, therefore leading to delayed diagnosis or misdiagnosis of BD as MDD, particularly bipolar II disorder (BD II) (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p><p>Delayed diagnosis and misdiagnosis of bipolar disorder may result in the use of antidepressant monotherapy, creating an increased risk of patients moving to a hypomanic or manic episode (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Approximately 40&#8211;60% of patients with bipolar disorder are initially diagnosed with MDD, and an accurate diagnosis or treatment of bipolar disorder may be delayed by 5&#8211;10 years (<xref rid="B7" ref-type="bibr">7</xref>). Definitive diagnosis and treatment are critical to improving psychiatric disorders&#8217; symptoms and functional prognosis. On the contrary, under-treatment and delayed treatment increase both the direct and indirect economic costs associated with BD, result in increase individual suffering, and compromise overall prognosis (<xref rid="B8" ref-type="bibr">8</xref>). In fact, a few pre-existing situations in MDD and BD diagnosis may add extra challenges to their under-treatment. Particularly, to date, the pathophysiological mechanisms of MDD and BD remain unclear, the objective biomarkers for differentiating these two disorders are still lacking, and many clinicians have been using subjective identification to diagnose MDD and BD based on symptom clustering from standardized structured diagnostic interviews. Therefore, searching for specific biomarkers to differentiate BD from MDD is crucial.</p><p>Metabolomics is a new addition to the field of histology, focusing on measuring the downstream effects of environmental, genomic, and proteomic variation in individuals by identifying and quantifying small molecules called metabolites (<xref rid="B9" ref-type="bibr">9</xref>). By assessing the abundance and type of metabolites detected, metabolomics can provide a functional readout of the cellular state within an individual and help us identify biochemical signatures or biomarkers specific to different diseases (<xref rid="B10" ref-type="bibr">10</xref>). Currently, metabolomics has unique and proven advantages in the development of biomarkers for several diseases (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). The serum is used in metabolomics studies and has been used for many common diseases such as cardiovascular injury, diabetes, Parkinson&#8217;s disease, and depression (<xref rid="B13" ref-type="bibr">13</xref>). The analytical techniques commonly used in metabolomics studies are nuclear magnetic resonance (NMR) and mass spectrometry (MS) (<xref rid="B14" ref-type="bibr">14</xref>). NMR has been widely used in current metabolomics research because of its advantages such as fast test speed, non-invasive and comprehensive metabolite information coverage.</p><p>Using an NMR metabolomics approach, our group has conducted several studies on the search for BD biomarkers in the early stages (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>). These identified biomarkers were able to accurately distinguish BD patients from healthy controls. However, the effectiveness of these biomarkers in discriminating BD from MDD remains unclear. To avoid misdiagnosis, previous studies have identified a number of candidate biomarkers to differentiate between MDD and BD patients (<xref rid="B18" ref-type="bibr">18</xref>&#8211;<xref rid="B21" ref-type="bibr">21</xref>). However, these putative biomarkers have not been used in clinical practice due to the high heterogeneity and overlapping dimensions between MDD and BD.</p><p>Therefore, in the present study, we used an NMR metabolomics approach to analyze serum metabolic phenotypes in BD, MDD, and healthy controls to initially explore biomarkers that may help differentiate BD and MDD and to further understand the pathophysiology of both diseases.</p></sec><sec sec-type="materials|methods" id="S2"><title>2. Materials and methods</title><sec id="S2.SS1"><title>2.1. Subject recruitment</title><p>Ethics approval for this study is held by the medical ethics committee of Shanxi Bethune Hospital (the Approval Notice Number: YXLL-2020-001). All subjects enrolled in the study gave their written informed consent. A pair of licensed, experienced psychiatrists were in charge of the recruiting procedure.</p><p>The current study was conducted at the Department of Psychiatry in Shanxi Bethune Hospital from July 2019 to February 2021. Fifty-nine patients with BD who fulfilled the bipolar depression criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) were recruited. MDD subjects were recruited from the same site and during the same time period. Fourteen candidates of MDD, who were diagnosed with MDD (Hamilton Depression Scale rating &#8805; 17) using the Structured Clinical Interview, were recruited. Patients with any physical or other mental disorders were excluded, as were patients who had substance abuse issues. To reduce the risk of misdiagnosed BD subjects among the MDD subjects included in this study, a licensed psychiatrist in our department who has specialized in the diagnosis and treatment of BD and MDD for several years systematically applied the validated structured interviews to diagnose each patient.</p><p>During the same time period, healthy controls (HC) were recruited from the Medical Examination Center in the same hospital. The candidates, who had no history of neurological, systemic medical illness, or DSM-IV Axis I/II illness, were recruited. Finally, 10 HC subjects were included. The demographic and clinical characteristics of the included subjects are shown in <xref rid="T1" ref-type="table">Table 1</xref>. The age of onset was defined as the age (in years) at which a patient first experienced the emotional symptoms described to a psychiatrist from the study&#8217;s research team. The duration of illness was the period (in months) from the first onset to the time of enrollment.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Clinicodemographic characteristics of the participants.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Variable</td><td valign="top" align="center" colspan="3" style="color:#ffffff;background-color: #7f8080;" rowspan="1">Group</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-value</td></tr></thead><tbody><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>BD (<italic toggle="yes">N</italic> = 59)</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>MDD (<italic toggle="yes">N</italic> = 14)</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>HC (<italic toggle="yes">N</italic> = 10)</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">27.73 &#177; 10.84</td><td valign="top" align="center" rowspan="1" colspan="1">33.12 &#177; 15.20</td><td valign="top" align="center" rowspan="1" colspan="1">28.5 &#177; 3.10</td><td valign="top" align="center" rowspan="1" colspan="1">0.271</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI</td><td valign="top" align="center" rowspan="1" colspan="1">22.40 &#177; 3.63</td><td valign="top" align="center" rowspan="1" colspan="1">22.79 &#177; 3.67</td><td valign="top" align="center" rowspan="1" colspan="1">21.6 &#177; 3.62</td><td valign="top" align="center" rowspan="1" colspan="1">0.271</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex (M/F)</td><td valign="top" align="center" rowspan="1" colspan="1">22/37</td><td valign="top" align="center" rowspan="1" colspan="1">7/7</td><td valign="top" align="center" rowspan="1" colspan="1">3/7</td><td valign="top" align="center" rowspan="1" colspan="1">0.570</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Onset age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">22.10 &#177; 9.60</td><td valign="top" align="center" rowspan="1" colspan="1">29.00 &#177; 15.56</td><td valign="top" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="center" rowspan="1" colspan="1">0.132</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of illness (months)</td><td valign="top" align="center" rowspan="1" colspan="1">39.39 &#177; 42.52</td><td valign="top" align="center" rowspan="1" colspan="1">33.93 &#177; 36.38</td><td valign="top" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="center" rowspan="1" colspan="1">0.659</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">The total scores of HAMD-24</td><td valign="top" align="center" rowspan="1" colspan="1">29.05 &#177; 7.60</td><td valign="top" align="center" rowspan="1" colspan="1">21.93 &#177; 10.37</td><td valign="top" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="center" rowspan="1" colspan="1">0.058</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as the mean (standard deviation).</p></fn><fn><p>BD, bipolar disorder; MDD, major depressive disorder; HC, healthy control; M/F, male/female; BMI, body mass index.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S2.SS2"><title>2.2. Sample collection</title><p>The blood samples of all subjects were collected by medical professionals at the Shanxi Bethune Hospital in the morning after a 12-h fast. The blood was mixed inverted after clotting and stored for 30 min at room temperature (about 20&#176;C) before centrifugation at 3,000 rpm for 15 min. Then, the serum was collected and stored in a &#8722;80&#176;C refrigerator for future use.</p></sec><sec id="S2.SS3"><title>2.3. NMR acquisition</title><p>The serum samples were thawed in ice water, and 450 &#956;L supernatant was removed and placed into an EP tube, 350 &#956;L D2O was added, and the mixture was centrifuged at 4&#176;C for 20 min (13000 r/min). Then, 600 &#956;L supernatant was transferred to a 5 mm NMR tube and stored at 4&#176;C until the NMR test. NMR was performed using a Bruker 600 MHz AVANCE III NMR spectrometer, with Carr-Purcell Meiboom-Gill pulse sequence, and the following parameter settings: free induction attenuation (64K data points), self-axonal relaxation delay (320 ms), 64 scans.</p></sec><sec id="S2.SS4"><title>2.4. Data processing</title><p>All the acquired <sup>1</sup>H NMR spectra were manually phased, and the baseline was set using MestReNova software (Mestrelab Research, Santiago de Compostella, Spain). All the serum <sup>1</sup>H NMR profiles were Fourier transformed and phase baseline adjusted. Chemical shift correction was performed on the profiles based on creatinine (&#948; 3.04, -CH3). The region of &#948; 4.70&#8211;5.20 ppm was excluded due to residual water. The data were then normalized to the total sum of the spectra.</p></sec><sec id="S2.SS5"><title>2.5. Statistical analysis</title><p>Partial least square discriminant (PLS-DA) analysis was performed, followed by orthogonal partial least square discriminant (OPLS-DA) analysis using SIMCA-P 14.1. To determine the pathways involved in differentially occurring metabolites, they were further introduced to MetaboAnalyst 5.0<sup><xref rid="footnote1" ref-type="fn">1</xref></sup> to perform pathway analysis using the human pathway library. Pathways were screened according to the <italic toggle="yes">p</italic>-values of pathway enrichment and impact values of pathway topology analysis.</p><p>The <italic toggle="yes">t</italic>-test was used to detect and identify differences in markers between BD and MDD. All clinical scale data were expressed as the mean &#177; SD. Continuous variables were analyzed using a one-way analysis of variance, while categorical variables were analyzed using the Chi-square test. All statistical analyses were performed using SPSS 20.0 (IBM, Chicago, IL, United States). A <italic toggle="yes">p</italic>-value of &#8804;0.05 was considered statistically significant for demographic analysis.</p></sec></sec><sec sec-type="results" id="S3"><title>3. Results</title><sec id="S3.SS1"><title>3.1. Clinical characteristics</title><p>There were no significant differences in age, education, or sex ratio (male/female) among the BD, MDD, and HC. There were also no significant differences between the BD and MDD groups concerning the age at onset, duration of illness, and HAMD scores. <xref rid="T1" ref-type="table">Table 1</xref> shows the clinicodemographic data of the participants.</p></sec><sec id="S3.SS2"><title>3.2. <sup>1</sup>H NMR spectroscopy data analysis</title><p>According to previous literature and the NMR data website (HMDB),<sup><xref rid="footnote2" ref-type="fn">2</xref></sup> the chemical shift, peak shape, and coupling constant of each metabolite were confirmed, and the <sup>1</sup>H-NMR metabolite maps of the blank, BD, and MDD groups were obtained (<xref rid="F1" ref-type="fig">Figure 1</xref>), from which 29 small-molecule compounds were identified (<xref rid="T2" ref-type="table">Table 2</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Typical <sup>1</sup>H NMR spectrum of serum in MDD, BD, and healthy controls groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g001.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Peak attribution in <sup>1</sup>H-NMR spectra of differential metabolites among the three groups.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">No</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Metabolites</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Chemical shift</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">Lipids</td><td valign="top" align="center" rowspan="1" colspan="1">0.874 (m)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Pantothenate</td><td valign="top" align="center" rowspan="1" colspan="1">0.907 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">Isoleucine</td><td valign="top" align="center" rowspan="1" colspan="1">0.949 (t)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">Leucine</td><td valign="top" align="center" rowspan="1" colspan="1">0.961 (t)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">3-Hydroxybutyric acid</td><td valign="top" align="center" rowspan="1" colspan="1">1.21 (d)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">Lactate</td><td valign="top" align="center" rowspan="1" colspan="1">1.33 (d)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">Acetic acid/Acetate</td><td valign="top" align="center" rowspan="1" colspan="1">1.927 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">O-Acetyl glycoproteins</td><td valign="top" align="center" rowspan="1" colspan="1">2.14 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="center" rowspan="1" colspan="1">Acetoacetate</td><td valign="top" align="center" rowspan="1" colspan="1">2.28 (s), 3.44 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">&#946;-glucose</td><td valign="top" align="center" rowspan="1" colspan="1">3.25 (dd, 9.4 Hz, 8.1 Hz)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">Guanidinoacetate</td><td valign="top" align="center" rowspan="1" colspan="1">3.80 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">Pyruvate</td><td valign="top" align="center" rowspan="1" colspan="1">2.37 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">Histidine</td><td valign="top" align="center" rowspan="1" colspan="1">7.04 (s), 7.84 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">Dimethylglycine</td><td valign="top" align="center" rowspan="1" colspan="1">2.92 (s), 3.70 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">Creatine</td><td valign="top" align="center" rowspan="1" colspan="1">3.04 (s), 3.93 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">Acetylcholine</td><td valign="top" align="center" rowspan="1" colspan="1">3.23 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">Taurine</td><td valign="top" align="center" rowspan="1" colspan="1">3.27 (t, <italic toggle="yes">J</italic> = 6.6 Hz), 3.42 (t, <italic toggle="yes">J</italic> = 6.6 Hz)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="center" rowspan="1" colspan="1">Mannose</td><td valign="top" align="center" rowspan="1" colspan="1">5.19 (d, 1.6 Hz)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="center" rowspan="1" colspan="1">3-D-hydroxybutyrate</td><td valign="top" align="center" rowspan="1" colspan="1">1.20 (d)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">Betaine</td><td valign="top" align="center" rowspan="1" colspan="1">3.27 (m)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">Glycerol</td><td valign="top" align="center" rowspan="1" colspan="1">3.67 (m), 3.78 (m)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">22</td><td valign="top" align="center" rowspan="1" colspan="1">Citrulline</td><td valign="top" align="center" rowspan="1" colspan="1">3.73 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">N-Acetyl glycoproteins</td><td valign="top" align="center" rowspan="1" colspan="1">2.05 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">Glutamate</td><td valign="top" align="center" rowspan="1" colspan="1">2.06 (m), 2.14 (m), 2.36 (m)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">Glutamine</td><td valign="top" align="center" rowspan="1" colspan="1">2.14 (m)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="center" rowspan="1" colspan="1">Acetone</td><td valign="top" align="center" rowspan="1" colspan="1">2.23 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="center" rowspan="1" colspan="1">Acetoacetate</td><td valign="top" align="center" rowspan="1" colspan="1">2.28 (s), 3.44 (s)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="center" rowspan="1" colspan="1">Citric acid/citrate</td><td valign="top" align="center" rowspan="1" colspan="1">2.53 (d, 16.1 Hz), 2.70 (d, 16.1 Hz)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">Choline</td><td valign="top" align="center" rowspan="1" colspan="1">3.20 (s), 4.06 (m)</td></tr></tbody></table></table-wrap></sec><sec id="S3.SS3"><title>3.3. Discriminative model construction</title><p>All serum samples were analyzed by <sup>1</sup>H NMR metabolic profiling using supervised PLS-DA, and the results were shown in <xref rid="F2" ref-type="fig">Figure 2A</xref>, indicating that the HC group was completely separated from the BD and MDD groups. Model verification results are shown in <xref rid="F2" ref-type="fig">Figure 2B</xref>. The results show that the PLS-DA model is effective.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>PLS-DA analysis of <sup>1</sup>H NMR spectra of serum samples from BD, MDD, and HC groups. <bold>(A)</bold> PLS-DA score plots of <sup>1</sup>H NMR spectra from BD (circle), MDD (square), and HC group (triangle); <bold>(B)</bold> PLS-DA model validation map.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g002.jpg"/></fig><p><xref rid="F2" ref-type="fig">Figure 2A</xref> shows that there is no significant difference between the BD group and the MDD group. Therefore, we analyzed and compared the BD group and the MDD group with the HC group respectively to further identify the metabolites changes and analyze their changing trends.</p><p><xref rid="F3" ref-type="fig">Figure 3A</xref> shows the differential metabolites of the healthy and BD groups analyzed using PCA (Principal Component Analysis). As shown in the figure, the HC and BD groups were significantly separated, indicating that the model was successfully replicated. To reduce intragroup error, PLS-DA profile analysis was performed for the HC group and BD group (<xref rid="F3" ref-type="fig">Figure 3B</xref>). The groups were significantly separated along T [1], and the model was verified 200 times to prove its validity (<xref rid="F3" ref-type="fig">Figure 3C</xref>). OPLS-DA analysis was performed to reduce the random errors unrelated to the target in the group and to identify the differential metabolites between the blank group and the BD group, as shown in <xref rid="F4" ref-type="fig">Figure 4A</xref>. The differential metabolites with VIP &gt; 1 were identified according to the S-plots (<xref rid="F4" ref-type="fig">Figure 4B</xref>), and an independent sample <italic toggle="yes">t</italic>-test was performed to screen out the metabolites with significant differences (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">p</italic> &lt; 0.01).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Metabolomics analysis of serum samples from HCs and patients with BD. <bold>(A)</bold> PCA (Principal Component Analysis) model; <bold>(B)</bold> PLS-DA model; <bold>(C)</bold> 200-iteration permutation test map of the PLS-DA model.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>OPLS-DA analysis of <sup>1</sup>H NMR spectra of serum samples from HCs and patients with BD. <bold>(A)</bold> Score plots of OPLS-DA model; <bold>(B)</bold> S-plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g004.jpg"/></fig><p>Similarly, the group of MDD was significantly separated from HC group in the PCA (<xref rid="F5" ref-type="fig">Figure 5A</xref>) and PLS-DA model (<xref rid="F5" ref-type="fig">Figure 5B</xref>), which were verified to be valid by the permutation testing (<xref rid="F5" ref-type="fig">Figure 5C</xref>). The score plot of OPLS-DA model (<xref rid="F6" ref-type="fig">Figure 6A</xref>) and the corresponding S-plot (<xref rid="F6" ref-type="fig">Figure 6B</xref>) indicated the differential metabolites (VIP &gt; 1, <italic toggle="yes">p</italic> &lt; 0.05).</p><fig position="float" id="F5" orientation="portrait"><label>FIGURE 5</label><caption><p>Metabolomics analysis of serum samples from HCs and patients with MDD. <bold>(A)</bold> PCA (Principal Component Analysis) model; <bold>(B)</bold> PLS-DA model; <bold>(C)</bold> 200-iteration permutation test map of the PLS-DA model.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g005.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>FIGURE 6</label><caption><p>OPLS-Da analysis of <sup>1</sup>H NMR spectra of serum samples from HCs and patients with MDD. <bold>(A)</bold> Score plots of OPLS-DA model; <bold>(B)</bold> S-plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g006.jpg"/></fig></sec><sec id="S3.SS4"><title>3.4. Differences in the serum metabolite and metabolic pathways between the BD and HC groups</title><p><xref rid="T3" ref-type="table">Table 3</xref> shows the influence of potential biomarkers in the BD group. With the HC group as reference and VIP &gt; 1 and <italic toggle="yes">p</italic> &lt; 0.05, nine metabolites differentially expressed in the BD group were identified. 3-hydroxybutyric acid, N-acetyl glycoproteins, &#946;-glucose, pantothenate, mannose, glycerol, and lipids levels were significantly higher in the BD group (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">p</italic> &lt; 0.01), while lactate and acetoacetate levels were significantly lower (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">p</italic> &lt; 0.01). The relative concentrations of the nine identified metabolites are shown in <xref rid="F7" ref-type="fig">Figure 7</xref>. The results of Metabo Analyst 5.0 analysis are presented graphically as a bubble plot in <xref rid="F8" ref-type="fig">Figure 8</xref>. The darker color and larger size represent higher <italic toggle="yes">p</italic>-values from enrichment analysis and greater impact from pathway topology analysis, respectively. This model is mainly related to: (1) glycolysis/gluconeogenesis; (2) glycerolipid metabolism; (3) synthesis and degradation of ketone bodies; (4) butanoate metabolism; (5) pantothenate and COA; (6) pyruvate metabolism; and (7) galactose metabolism.</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Peak area of metabolites in serum <sup>1</sup>H-NMR spectra of the HC and BD groups.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Metabolites</td><td valign="top" align="center" colspan="2" style="color:#ffffff;background-color: #7f8080;" rowspan="1">Peak area after normalization</td></tr></thead><tbody><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>HC</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>BD</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3- -hydroxybutyric acid</td><td valign="top" align="center" rowspan="1" colspan="1">0.549 &#177; 1.048</td><td valign="top" align="center" rowspan="1" colspan="1">2.019 &#177; 1.272</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">N- -acetyl glycoproteins</td><td valign="top" align="center" rowspan="1" colspan="1">0.185 &#177; 0.156</td><td valign="top" align="center" rowspan="1" colspan="1">0.378 &#177; 0.145</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#946;-glucose</td><td valign="top" align="center" rowspan="1" colspan="1">0.75 &#177; 0.124</td><td valign="top" align="center" rowspan="1" colspan="1">0.95 &#177; 0.211</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pantothenate</td><td valign="top" align="center" rowspan="1" colspan="1">0.293 &#177; 0.086</td><td valign="top" align="center" rowspan="1" colspan="1">0.389 &#177; 0.092</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mannose</td><td valign="top" align="center" rowspan="1" colspan="1">0.069 &#177; 0.167</td><td valign="top" align="center" rowspan="1" colspan="1">0.565 &#177; 0.317</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glycerol</td><td valign="top" align="center" rowspan="1" colspan="1">0.609 &#177; 0.156</td><td valign="top" align="center" rowspan="1" colspan="1">0.954 &#177; 0.273</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lactate</td><td valign="top" align="center" rowspan="1" colspan="1">0.428 &#177; 0.200</td><td valign="top" align="center" rowspan="1" colspan="1">0.139 &#177; 0.183</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acetoacetate</td><td valign="top" align="center" rowspan="1" colspan="1">0.597 &#177; 0.164</td><td valign="top" align="center" rowspan="1" colspan="1">0.346 &#177; 0.166</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lipids</td><td valign="top" align="center" rowspan="1" colspan="1">0.343 &#177; 0.102</td><td valign="top" align="center" rowspan="1" colspan="1">0.443 &#177; 0.114</td></tr></tbody></table></table-wrap><fig position="float" id="F7" orientation="portrait"><label>FIGURE 7</label><caption><p>Differential metabolites level in serum <sup>1</sup>H NMR spectra of the HC and BD groups. Compared with control group, *<italic toggle="yes">P</italic> &lt; 0.05 and **<italic toggle="yes">P</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g007.jpg"/></fig><fig position="float" id="F8" orientation="portrait"><label>FIGURE 8</label><caption><p>Metabolic pathways analysis of the differential metabolites between the HC and BD groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g008.jpg"/></fig></sec><sec id="S3.SS5"><title>3.5. Differences in the serum metabolite and metabolic pathway between the MDD and HC groups</title><p><xref rid="T4" ref-type="table">Table 4</xref> shows the potential biomarkers in the serum of patients with MDD. With the HC group as a reference and VIP &gt; 1 and <italic toggle="yes">p</italic> &lt; 0.05, eight metabolites differentially expressed in the MDD group were identified. 3-Hydroxybutyric acid, N-acetyl glycoproteins, pyruvate, choline, acetoacetate, and lipids levels were significantly higher in the MDD group (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">p</italic> &lt; 0.01), while acetic acid and glyceryl level were significantly lower (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">p</italic> &lt; 0.01). The relative concentrations of the eight identified metabolites are shown in <xref rid="F9" ref-type="fig">Figure 9</xref>. The results of the MetaboAnalyst 5.0 analysis are shown in <xref rid="F10" ref-type="fig">Figure 10</xref>. This model is mainly related to: (1) pyruvate metabolism; (2) glycolysis/gluconeogenesis; (3) glyoxylate and dicarboxylate metabolism; (4) glycine, serine and threonine metabolism; (5) synthesis and degradation of ketone bodies; (6) glycerolipid metabolism; (7) butanoate metabolism; (8) citrate cycle; and (9) glycerophospholipid metabolism.</p><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>Peak area of metabolites in serum <sup>1</sup>H-NMR spectra of the HC and MDD groups.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Metabolites</td><td valign="top" align="center" colspan="2" style="color:#ffffff;background-color: #7f8080;" rowspan="1">Peak area after normalization</td></tr></thead><tbody><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>HC</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>MDD</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3-hydroxybutyric acid</td><td valign="top" align="center" rowspan="1" colspan="1">0.125 &#177; 0.99</td><td valign="top" align="center" rowspan="1" colspan="1">0.35 &#177; 1.69</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">N-acetyl glycoproteins</td><td valign="top" align="center" rowspan="1" colspan="1">0.185 &#177; 0.156</td><td valign="top" align="center" rowspan="1" colspan="1">0.41 &#177; 0.187</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pyruvate</td><td valign="top" align="center" rowspan="1" colspan="1">0.125 &#177; 0.105</td><td valign="top" align="center" rowspan="1" colspan="1">0.309 &#177; 0.147</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Choline</td><td valign="top" align="center" rowspan="1" colspan="1">0.099 &#177; 0.011</td><td valign="top" align="center" rowspan="1" colspan="1">0.386 &#177; 0.243</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acetic acid</td><td valign="top" align="center" rowspan="1" colspan="1">0.702 &#177; 0.136</td><td valign="top" align="center" rowspan="1" colspan="1">0.455 &#177; 0.209</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glyceryl</td><td valign="top" align="center" rowspan="1" colspan="1">0.756 &#177; 0.139</td><td valign="top" align="center" rowspan="1" colspan="1">0.583 &#177; 0.205</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acetoacetate</td><td valign="top" align="center" rowspan="1" colspan="1">0.082 &#177; 0.032</td><td valign="top" align="center" rowspan="1" colspan="1">0.124 &#177; 0.389</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lipids</td><td valign="top" align="center" rowspan="1" colspan="1">0.343 &#177; 0.102</td><td valign="top" align="center" rowspan="1" colspan="1">0.443 &#177; 0.114</td></tr></tbody></table></table-wrap><fig position="float" id="F9" orientation="portrait"><label>FIGURE 9</label><caption><p>Differential metabolites level in serum <sup>1</sup>H NMR spectra of the HC and MDD groups. Compared with control group, *<italic toggle="yes">P</italic> &lt; 0.05 and **<italic toggle="yes">P</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g009.jpg"/></fig><fig position="float" id="F10" orientation="portrait"><label>FIGURE 10</label><caption><p>Metabolic pathways analysis of the differential metabolites between the HC and MDD groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1251955-g010.jpg"/></fig></sec></sec><sec sec-type="discussion" id="S4"><title>4. Discussion</title><p>In clinical practice, BD cases are often misdiagnosed as MDD (<xref rid="B22" ref-type="bibr">22</xref>), so finding specific markers to distinguish BD from MDD is crucial. The results of several previous studies have explored the biomarker differences between BD and MDD. For example, one study found that patients with BD and MDD had significantly different features on magnetic resonance imaging (MRI) of the brain, suggesting different neurobiological mechanisms between BD and MDD (<xref rid="B23" ref-type="bibr">23</xref>). However, there are still no biomarkers that can accurately distinguish between BD and MDD, and although there are many studies related to the search for biomarkers in the field of metabolomics for BD and MDD, there are only a few reports that include both groups in the study. In this study, we analyzed the serum metabolic phenotypes of BD, MDD, and healthy controls using an NMR metabolomics platform with the aim of exploring whether there are biomarkers that can distinguish BD from MDD. The results showed that the metabolic phenotypes of the BD and MDD groups were significantly different from those of healthy controls, indicating that metabolic changes in those two diseases were significantly different from those in healthy individuals and that there were different metabolite differences between them. Specifically, in the BD group, the levels of 3-hydroxybutyric acid, n-acetyl glycoprotein, &#946;-glucose, pantothenic acid, mannose, glycerol, and lipids were significantly higher than those in healthy controls, while the levels of lactate and acetoacetate were significantly lower than those in healthy controls. In contrast, in the MDD group, the levels of 3-hydroxybutyric acid, n-acetyl glycoprotein, pyruvate, choline, acetoacetic acid, and lipids were significantly higher than those in the healthy control group, while the levels of acetic acid and glycerol were significantly lower than those in the healthy control group.</p><p>These differential metabolites above may provide initial insights into the metabolic differences between BD and MDD. Despite the differences in metabolites between MDD and BD, the results of the pathway analysis suggest that most of the most important pathways are shared in these diseases, which is consistent with the findings of previous studies. Notably, most of the key metabolites and their associated pathways appear to focus on three common themes, namely (1) mitochondrial/energy metabolism, (2) neuronal integrity, and (3) signaling/neurotransmission, as described below.</p><p>Our study found that lactate and acetoacetate were significantly lower in the BD group. Imbalance in energy homeostasis in BD has been previously reported (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Previous studies had shown that lactate and acetoacetate were metabolites produced in the process of producing ATP, which plays an important role in many cellular metabolic processes. The results of this study suggest that the energy metabolic status of BD patients may be lower than that of the normal population. Similarly, elevated levels of glycerol and lipids have been associated with the pathogenesis of BD. Previous studies have suggested that dysregulated lipid metabolism in BD patients may be associated with inflammation and brain atrophy. One of these studies found that serum levels of triacylglycerol and cholesterol were significantly higher in BD patients than in controls, whereas HDL levels were significantly lower, which may correlate with the level of inflammation and the degree of brain atrophy in BD patients. Another study also found abnormalities in lipid metabolism in the brain tissue of BD patients, including abnormal accumulation of triglycerides and cholesterol and abnormal degradation and synthesis of myelin proteins in neurons and glial cells. All of these abnormalities may have an impact on neurological function in BD patients, leading to the development of symptoms of mood disorders. Furthermore, Liu et al. (<xref rid="B26" ref-type="bibr">26</xref>) found that phospholipid levels were significantly elevated in MDD patients and that these levels were positively correlated with the severity of depression. Consistent with previous studies, we found that abnormal lipid levels were present in both BD and MDD and those glycerolipid metabolic pathways were significantly involved in the development of BD and MDD. Several previous studies have confirmed that disorders or abnormalities of lipid metabolism were associated with neuropsychiatric disorders, such as BD, schizophrenia, and major depressive disorder. Therefore, disorders of lipid metabolism may be an important pathogenesis of BD and MDD and an important cause of the disease.</p><p>In addition, the present study found that &#946;-glucose and mannose were significantly elevated in the BD group and that glycolysis/gluconeogenesis was a common metabolic pathway in BD and MDD. Previous studies have shown that there was glucose impairment during some severe psychiatric episodes, even before the start of treatment (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Recently, extremely high levels of sugar metabolites (sorbitol, gluconate, xylitol, liothymol, arabinitol, and erythritol) and brain glycitol (inositol) have been detected in the brains of patients with bipolar disorder. An autopsy study suggested that abnormal metabolism of sugar and branched-chain amino acids may be a key factor in the pathogenesis of bipolar disorder and that antidiabetic treatment may be beneficial in the treatment of psychiatric disorders (<xref rid="B29" ref-type="bibr">29</xref>). Lipid and glucose metabolism was also higher in patients with MDD than in HC (<xref rid="B30" ref-type="bibr">30</xref>). Another study found that patients with first-episode depression had significantly higher glucose and triglyceride levels than healthy subjects (<xref rid="B31" ref-type="bibr">31</xref>). Singh et al. (<xref rid="B32" ref-type="bibr">32</xref>) also suggested that depression was closely associated with diabetes and cerebrovascular disease. Therefore, the use of the glucose-lipid signaling pathway to predict MDD should take diabetes and CVD into account. The absence of abnormal glucose metabolites in the MDD group in our study may be related to its small sample size.</p><p>Our study also found that pyruvate and choline were significantly elevated and acetic acid was significantly decreased in the MDD group, while these metabolites were not significantly altered in the BD group. Alterations in choline metabolism are associated with disruptions in intraneural signaling (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>), and in addition, the cholinergic hypothesis of depression suggests that cholinergic overactivity and Andr&#233;gic hypoactivity lead to depressive states (<xref rid="B35" ref-type="bibr">35</xref>). In contrast, choline levels correlate with the clinical state of depression (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>), suggesting that choline may be involved in the pathogenesis of depression. As was the case in the present study, a variety of molecules, including acetate and pyruvate, may be MDD-specific drug candidates, and these molecules may lead to more targeted treatment of depressive symptoms, as reported in a review (<xref rid="B38" ref-type="bibr">38</xref>). Other studies have also reported that pyruvate levels in the MDD patient group correlate with the severity of depression and may be a potential biomarker candidate for MDD. Pyruvate, as the carboxylate anion of pyruvate, is an end product of glycolysis and can be further involved in the TCA cycle, which is a major process of energy metabolism (<xref rid="B39" ref-type="bibr">39</xref>). However, contrary to the results observed in the present study, the review also mentioned that both MDD and BD patients showed a trend of upregulation of choline and lactate in their brains, while the study mentioned that BD serum studies identified seven biomarkers in one or more studies, including pyruvate (<xref rid="B38" ref-type="bibr">38</xref>). Lactate and pyruvate were found to be abnormal in BD cerebrospinal fluid biomarkers in more than one study. Therefore, the absence of choline and pyruvate in the BD group in this study may be related to a single metabolic platform, insufficient sample size, and drug effects. In addition, we found that the pyruvate metabolic pathway was significantly, although not significantly, involved in the development of MDD, as well as BD. Therefore, the exact mechanisms of pyruvate pathway alterations in psychiatric disorders need to be further explored. Whether pyruvate, choline, and acetate can serve as potential biomarkers for MDD to distinguish it from BD still needs to be verified by numerous replicated studies in the future. Given that pyruvate provides energy to living cells via the citric acid cycle, our findings also confirm that the aberrant citric acid cycle in mitochondria may be involved in the pathogenesis of BD and MDD.</p><p>In the present study, 3-hydroxybutyric acid was the metabolite that jointly distinguishes BD and MDD from HC. In a previous study (<xref rid="B40" ref-type="bibr">40</xref>), this biomarker was associated with MDD. 3-hydroxybutyric acid (&#946;-hydroxybutyric acid) is a ketone, a marker known to favor lipid rather than glucose metabolism. 3-hydroxybutyric acid is a ketone elevated in the blood and urine in ketosis. During hypoglycemia, it can be metabolized by the brain for energy (<xref rid="B41" ref-type="bibr">41</xref>). Recent studies have shown that 3-hydroxybutyric acid, a metabolite used as a source of energy in the brain, was associated with inflammation of the brain, specifically leading to epilepsy (<xref rid="B42" ref-type="bibr">42</xref>). The current data suggest that 3-hydroxybutyrate itself may control the emotional system in the brain through energy metabolite processes (<xref rid="B40" ref-type="bibr">40</xref>).</p><p>What&#8217;s more, we found elevated pantothenic acid levels in the BD group compared to the MDD group, which is consistent with the findings of a previous study that found significantly lower vitamin B12 levels in patients with BD, which may lead to elevated pantothenic acid levels. Pantothenic acid itself is a component of coenzyme a and a precursor of NAA, which is abundant in neurons and is considered an indicator of mitochondrial dysfunction and a marker of neuronal integrity and viability (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Interestingly, animal studies have shown that levels of NAA are not static and can be reversed by the use of antidepressants, suggesting that antidepressants have neurotrophic effects (<xref rid="B45" ref-type="bibr">45</xref>). And whether pantothenic acid can be used as a potential biomarker for BD to distinguish from MDD also needs to be verified in later large-scale studies.</p><p>Mays et al. (<xref rid="B46" ref-type="bibr">46</xref>) found significant changes in glycine, serine and threonine levels in patients with refractory depression, which is consistent with the findings of the present study that found abnormal glycine, serine and threonine metabolic pathways in MDD subjects, and our previous study also found a high correlation between glycine, serine and threonine metabolism and bipolar depression (<xref rid="B47" ref-type="bibr">47</xref>). Glycine or serine combined with glutamate as a coagonist can help activate N-methyl-D-aspartate receptors (NMDARs) (<xref rid="B48" ref-type="bibr">48</xref>), and abnormalities in NMDAR activity has been shown to cause affective and cognitive impairment, the core symptom of affective disorders, by decreasing neuroplasticity (<xref rid="B49" ref-type="bibr">49</xref>). Reducing serine levels impairs NMDAR-mediated processes in the hippocampus, prefrontal cortex, and amygdala (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>), brain structures that are strongly associated with mood disorders (<xref rid="B52" ref-type="bibr">52</xref>). We thus hypothesize that this metabolic pathway may be involved in the pathogenesis of mood disorders.</p><p>This is only a preliminary study of the differential diagnosis of BD and MDD based on metabolomics biomarkers and serum metabolic pathways, and the results suggest that it is feasible to find biomarkers in the field of metabolomics to differentiate BD and MDD, and also that these differential metabolites may be used as future biomarkers for the diagnosis of BD and MDD in clinical practice. However, the study also has some limitations. First, this study used a small sample size study with a small sample size, which may affect the stability and reliability of the results. Second, other factors, such as diet, body weight, and medication, may also affect the metabolic phenotype of BD and MDD, and the effects of these factors need to be further explored in future studies. Third, it is important to note that the metabolomics platform used in this study may have limitations, as different metabolomics platforms have different sensitivity and accuracy for the detection of different metabolites. Therefore, future studies will need to be validated using multiple metabolomics platforms to further determine the specificity and accuracy of these differential metabolites. Another potential limitation is that our study was a cross-sectional study and could not determine the relationship between metabolite levels and disease progression.</p><p>Overall, the present study provides useful clues for finding biomarkers to differentiate BD from MDD and highlights the importance of metabolomics in this field, but more studies are needed to further confirm the reliability of these findings and the potential for clinical application. In addition, a deeper understanding of the pathophysiological mechanisms of BD and MDD is also needed to help us better understand the differences in metabolic phenotypes and thus better identify and treat both diseases.</p></sec><sec sec-type="conclusion" id="S5"><title>5. Conclusion</title><p>In summary, this study used an NMR metabolomics platform to explore the metabolic phenotypic differences between BD and MDD, and found that the metabolic phenotypes of BD and MDD were significantly different from those of healthy controls. Glycerolipid metabolism was significantly involved in BD and MDD. Pyruvate metabolism was significantly involved in MDD. Pyruvate, choline, and acetate may be potential biomarkers for MDD to distinguish from BD, and pantothenic acid may be a potential biomarker for BD to distinguish from MDD. The clinical significance of this study is the discovery of different metabolic phenotypes between BD and MDD, as well as of potential biomarkers for distinguishing BD from MDD. Our findings contribute to the future development of an objective laboratory-based diagnostic test to distinguish between BD and MDD patients, which is very meaningful for the precise diagnosis and treatment of clinical psychiatric disorders. Future studies require more rigorous experimental designs, larger sample sizes, and longitudinal studies to validate our results and conclusions.</p></sec><sec sec-type="data-availability" id="S6"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.</p></sec><sec sec-type="ethics-statement" id="S7"><title>Ethics statement</title><p>The studies involving humans were approved by the Medical Ethics Committee of Shanxi Bethune Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="S8"><title>Author contributions</title><p>X-LS, L-NM, and YR contributed to the manuscript preparation. X-LS, L-NM, and Z-ZC performed the data analysis and statistics. JJ and Y-BX oversaw the data/demographic data collection. YW and YR were in charge of design and implementation of the study and contributed to the data interpretation. All authors contributed to the article and approved the submitted version.</p></sec></body><back><ack><p>We thank all the subjects for participating in this study.</p></ack><fn-group><fn id="footnote1"><label>1</label><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.metaboanalyst.ca/" ext-link-type="uri">http://www.metaboanalyst.ca/</ext-link>
</p></fn><fn id="footnote2"><label>2</label><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.hmdb.ca/" ext-link-type="uri">http://www.hmdb.ca/</ext-link>
</p></fn></fn-group><sec sec-type="COI-statement" id="S10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="S11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battle</surname><given-names>DE</given-names></name></person-group>. <article-title>Diagnostic and statistical manual of mental disorders (DSM)</article-title>. <source><italic toggle="yes">Codas</italic></source> (<year>2013</year>) <volume>25</volume>:<fpage>191</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1590/s2317-17822013000200017</pub-id><pub-id pub-id-type="pmid">24413388</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Judd</surname><given-names>L</given-names></name><name name-style="western"><surname>Akiskal</surname><given-names>H</given-names></name><name name-style="western"><surname>Schettler</surname><given-names>P</given-names></name><name name-style="western"><surname>Coryell</surname><given-names>W</given-names></name><name name-style="western"><surname>Endicott</surname><given-names>J</given-names></name><name name-style="western"><surname>Maser</surname><given-names>J</given-names></name><etal/></person-group><article-title>A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.</article-title><source><italic toggle="yes">Arch Gen Psychiatry.</italic></source> (<year>2003</year>) <volume>60</volume>:<fpage>261</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.60.3.261</pub-id><pub-id pub-id-type="pmid">12622659</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>E</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>M</given-names></name><name name-style="western"><surname>Hood</surname><given-names>K</given-names></name><name name-style="western"><surname>Craddock</surname><given-names>N</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>SA</given-names></name></person-group>. <article-title>Unrecognised bipolar disorder in primary care patients with depression.</article-title><source><italic toggle="yes">Br J Psychiatry.</italic></source> (<year>2011</year>). <volume>199</volume><fpage>49</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">21292927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.bp.110.083840</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angst</surname><given-names>J</given-names></name></person-group>. <article-title>Do many patients with depression suffer from bipolar disorder.</article-title><source><italic toggle="yes">Can J Psychiatry.</italic></source> (<year>2006</year>). <volume>51</volume>:<fpage>3</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">16491977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/070674370605100102</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viktorin</surname><given-names>A</given-names></name><name name-style="western"><surname>Lichtenstein</surname><given-names>P</given-names></name><name name-style="western"><surname>Thase</surname><given-names>ME</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>H</given-names></name><name name-style="western"><surname>Lundholm</surname><given-names>C</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>PK</given-names></name><etal/></person-group><article-title>The Risk of Switch to Mania in Patients with Bipolar Disorder during Treatment with an antidepressant alone and in combination with a mood stabilizer.</article-title><source><italic toggle="yes">Am J Psychiatry.</italic></source> (<year>2014</year>). <volume>171</volume>:<fpage>1067</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">24935197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2014.13111501</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Knight</surname><given-names>S</given-names></name><name name-style="western"><surname>Kamali</surname><given-names>M</given-names></name><name name-style="western"><surname>Assari</surname><given-names>S</given-names></name><name name-style="western"><surname>McInnis</surname><given-names>M</given-names></name></person-group>. <article-title>Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder.</article-title><source><italic toggle="yes">J Clin Psychiatry.</italic></source> (<year>2018</year>) <volume>79</volume>:<issue>17m11765</issue>. <pub-id pub-id-type="doi">10.4088/JCP.17m11765</pub-id><pub-id pub-id-type="pmid">29873955</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teneralli</surname><given-names>R</given-names></name><name name-style="western"><surname>Kern</surname><given-names>D</given-names></name><name name-style="western"><surname>Cepeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>J</given-names></name><name name-style="western"><surname>Drevets</surname><given-names>W</given-names></name></person-group>. <article-title>Exploring real-world evidence to uncover unknown drug benefits and support the discovery of new treatment targets for depressive and bipolar disorders.</article-title><source><italic toggle="yes">J Affect Disord.</italic></source> (<year>2021</year>) <volume>290</volume>:<fpage>324</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2021.04.096</pub-id><pub-id pub-id-type="pmid">34020207</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>McCrone</surname><given-names>P</given-names></name></person-group>. <article-title>Cost-of-illness studies for bipolar disorder: systematic review of international studies.</article-title><source><italic toggle="yes">Pharmacoeconomics.</italic></source> (<year>2015</year>) <volume>33</volume>:<fpage>341</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/s40273-014-0250-y</pub-id><pub-id pub-id-type="pmid">25576148</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patti</surname><given-names>G</given-names></name><name name-style="western"><surname>Yanes</surname><given-names>O</given-names></name><name name-style="western"><surname>Siuzdak</surname><given-names>G</given-names></name></person-group>. <article-title>Innovation: metabolomics: the apogee of the omics trilogy.</article-title><source><italic toggle="yes">Nat Rev Mol Cell Biol.</italic></source> (<year>2012</year>) <volume>13</volume>:<fpage>263</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3314</pub-id><pub-id pub-id-type="pmid">22436749</pub-id><pub-id pub-id-type="pmcid">PMC3682684</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>J</given-names></name><name name-style="western"><surname>Broadhurst</surname><given-names>D</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M</given-names></name><name name-style="western"><surname>Wishart</surname><given-names>D</given-names></name></person-group>. <article-title>Translational biomarker discovery in clinical metabolomics: an introductory tutorial.</article-title><source><italic toggle="yes">Metabolomics.</italic></source> (<year>2013</year>) <volume>9</volume>:<fpage>280</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1007/s11306-012-0482-9</pub-id><pub-id pub-id-type="pmid">23543913</pub-id><pub-id pub-id-type="pmcid">PMC3608878</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beger</surname><given-names>RD</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>W</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gross</surname><given-names>SS</given-names></name><name name-style="western"><surname>Kirwan</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cascante</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metabolomics enables precision medicine: &#8220;A White Paper, Community Perspective&#8221;.</article-title><source><italic toggle="yes">Metabolomics.</italic></source> (<year>2016</year>). <volume>12</volume>:<issue>149</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11306-016-1094-6</pub-id><pub-id pub-id-type="pmcid">PMC5009152</pub-id><pub-id pub-id-type="pmid">27642271</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riekeberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Powers</surname><given-names>R</given-names></name></person-group>. <article-title>New frontiers in metabolomics: from measurement to insight.</article-title><source><italic toggle="yes">F1000Res.</italic></source> (<year>2017</year>). <volume>6</volume>:<issue>1148</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.12688/f1000research.11495.1</pub-id><pub-id pub-id-type="pmcid">PMC5521158</pub-id><pub-id pub-id-type="pmid">28781759</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>W</given-names></name><name name-style="western"><surname>Broadhurst</surname><given-names>D</given-names></name><name name-style="western"><surname>Atherton</surname><given-names>H</given-names></name><name name-style="western"><surname>Goodacre</surname><given-names>R</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>J</given-names></name></person-group>. <article-title>Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy.</article-title><source><italic toggle="yes">Chem Soc Rev.</italic></source> (<year>2011</year>) <volume>40</volume>:<fpage>387</fpage>&#8211;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1039/b906712b</pub-id><pub-id pub-id-type="pmid">20717559</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>H</given-names></name><name name-style="western"><surname>Klassen</surname><given-names>A</given-names></name><name name-style="western"><surname>Pedrini</surname><given-names>M</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>M</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>L</given-names></name><name name-style="western"><surname>Noto</surname><given-names>M</given-names></name><etal/></person-group><article-title>A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics.</article-title><source><italic toggle="yes">Psychiatry Res.</italic></source> (<year>2017</year>) <volume>258</volume>:<fpage>268</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2017.08.039</pub-id><pub-id pub-id-type="pmid">28918859</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Metabolomic biomarkers related to non-suicidal self-injury in patients with bipolar disorder.</article-title><source><italic toggle="yes">BMC Psychiatry.</italic></source> (<year>2022</year>). <volume>22</volume>:<issue>491</issue>. <pub-id pub-id-type="doi">10.1186/s12888-022-04079-8</pub-id><pub-id pub-id-type="pmid">35869468</pub-id><pub-id pub-id-type="pmcid">PMC9306041</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Cui</surname><given-names>XH</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pre- and post-treatment levels of plasma metabolites in patients with bipolar depression.</article-title><source><italic toggle="yes">Front Psychiatry.</italic></source> (<year>2021</year>). <volume>12</volume>:<issue>747595</issue>. <pub-id pub-id-type="doi">10.3389/fpsyt.2021.747595</pub-id><pub-id pub-id-type="pmid">34975567</pub-id><pub-id pub-id-type="pmcid">PMC8718604</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>YB</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><name name-style="western"><surname>Cui</surname><given-names>XH</given-names></name><name name-style="western"><surname>Wu</surname><given-names>WZ</given-names></name><name name-style="western"><surname>Tian</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Altered metabolomics in bipolar depression with gastrointestinal symptoms.</article-title><source><italic toggle="yes">Front Psychiatry.</italic></source> (<year>2022</year>). <volume>13</volume>:<issue>861285</issue>. <pub-id pub-id-type="doi">10.3389/fpsyt.2022.861285</pub-id><pub-id pub-id-type="pmid">35686183</pub-id><pub-id pub-id-type="pmcid">PMC9170992</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeshima</surname><given-names>M</given-names></name><name name-style="western"><surname>Oka</surname><given-names>T</given-names></name></person-group>. <article-title>DSM-5-defined &#8220;mixed features&#8221; and Benazzi&#8217;s mixed depression: which is practically useful to discriminate bipolar disorder from unipolar depression in patients with depression?</article-title><source><italic toggle="yes">Psychiatry Clin Neurosci.</italic></source> (<year>2015</year>). <volume>69</volume>:<fpage>109</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">24902989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcn.12213</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Employing biochemical biomarkers for building decision tree models to predict bipolar disorder from major depressive disorder.</article-title><source><italic toggle="yes">J Affect Disord.</italic></source> (<year>2022</year>) <volume>308</volume>:<fpage>190</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2022.03.080</pub-id><pub-id pub-id-type="pmid">35439462</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>KL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>JW</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bai</surname><given-names>YM.</given-names></name><etal/></person-group><article-title>Using classification and regression tree modeling to investigate appetite hormones and proinflammatory cytokines as biomarkers to differentiate bipolar I depression from major depressive disorder.</article-title><source><italic toggle="yes">CNS Spectr.</italic></source> (<year>2021</year>). <comment>[Epub ahead of print]</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S109285292100016X</pub-id><pub-id pub-id-type="pmid">33563365</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis.</article-title><source><italic toggle="yes">Psychoneuroendocrinology.</italic></source> (<year>2017</year>). <volume>86</volume>:<fpage>17</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">28910601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2017.09.005</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mota</surname><given-names>R</given-names></name><name name-style="western"><surname>Gazal</surname><given-names>M</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>B</given-names></name><name name-style="western"><surname>de Leon</surname><given-names>P</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K</given-names></name><name name-style="western"><surname>Pinheiro</surname><given-names>R</given-names></name><etal/></person-group><article-title>Interleukin-1&#946; is associated with depressive episode in major depression but not in bipolar disorder.</article-title><source><italic toggle="yes">J Psychiatr Res.</italic></source> (<year>2013</year>) <volume>47</volume>:<fpage>2011</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.08.020</pub-id><pub-id pub-id-type="pmid">24074516</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kempton</surname><given-names>M</given-names></name><name name-style="western"><surname>Salvador</surname><given-names>Z</given-names></name><name name-style="western"><surname>Munaf&#242;</surname><given-names>M</given-names></name><name name-style="western"><surname>Geddes</surname><given-names>J</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A</given-names></name><name name-style="western"><surname>Frangou</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder.</article-title><source><italic toggle="yes">Arch Gen Psychiatry.</italic></source> (<year>2011</year>) <volume>68</volume>:<fpage>675</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.60</pub-id><pub-id pub-id-type="pmid">21727252</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshimi</surname><given-names>N</given-names></name><name name-style="western"><surname>Futamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Kakumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sellgren</surname><given-names>CM</given-names></name><name name-style="western"><surname>Holm&#233;n-Larsson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder.</article-title><source><italic toggle="yes">BBA Clin.</italic></source> (<year>2016</year>) <volume>5</volume>:<fpage>151</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27114925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbacli.2016.03.008</pub-id><pub-id pub-id-type="pmcid">PMC4832124</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansur</surname><given-names>RB</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>RS</given-names></name><name name-style="western"><surname>Brietzke</surname><given-names>E</given-names></name></person-group>. <article-title>What is bipolar disorder? A disease model of dysregulated energy expenditure.</article-title><source><italic toggle="yes">Neurosci Biobehav Rev.</italic></source> (<year>2020</year>). <volume>113</volume>:<fpage>529</fpage>&#8211;<lpage>545</lpage>.<pub-id pub-id-type="pmid">32305381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2020.04.006</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Plasma lipidomics reveals potential lipid markers of major depressive disorder.</article-title><source><italic toggle="yes">Anal Bioanal Chem.</italic></source> (<year>2016</year>) <volume>408</volume>:<fpage>6497</fpage>&#8211;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-016-9768-5</pub-id><pub-id pub-id-type="pmid">27457104</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calkin</surname><given-names>CV</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>DM</given-names></name><name name-style="western"><surname>Ransom</surname><given-names>T</given-names></name><name name-style="western"><surname>Alda</surname><given-names>M</given-names></name></person-group>. <article-title>The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders.</article-title><source><italic toggle="yes">Ann Med.</italic></source> (<year>2013</year>) <volume>45</volume>:<fpage>171</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">22621171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/07853890.2012.687835</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Rizo</surname><given-names>C</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>B</given-names></name><name name-style="western"><surname>Fernandez-Egea</surname><given-names>E</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>C</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>M</given-names></name></person-group>. <article-title>Abnormal glycemic homeostasis at the onset of serious mental illnesses: a common pathway.</article-title><source><italic toggle="yes">Psychoneuroendocrinology.</italic></source> (<year>2016</year>). <volume>67</volume>:<fpage>70</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">26878465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2016.02.001</pub-id><pub-id pub-id-type="pmcid">PMC4844848</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A</given-names></name><name name-style="western"><surname>Al Washih</surname><given-names>M</given-names></name><name name-style="western"><surname>Pickard</surname><given-names>B</given-names></name><name name-style="western"><surname>Watson</surname><given-names>D</given-names></name></person-group>. <article-title>Metabolomic profiling of post-mortem brain reveals changes in amino acid and glucose metabolism in mental illness compared with controls.</article-title><source><italic toggle="yes">Comput Struct Biotechnol J.</italic></source> (<year>2016</year>) <volume>14</volume>:<fpage>106</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2016.02.003</pub-id><pub-id pub-id-type="pmid">27076878</pub-id><pub-id pub-id-type="pmcid">PMC4813093</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Predictive diagnosis of major depression using NMR-based metabolomics and least-squares support vector machine.</article-title><source><italic toggle="yes">Clin Chim Acta.</italic></source> (<year>2017</year>) <volume>464</volume>:<fpage>223</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2016.11.039</pub-id><pub-id pub-id-type="pmid">27931880</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Q-C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G-H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H-L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z-B</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group>. <article-title>Study of metabolism of glucose and lipid in patients with first-episode depression</article-title>. <source><italic toggle="yes">J Clin Psychiatry.</italic></source> (<year>2009</year>) <volume>19</volume>:<fpage>241</fpage>&#8211;<lpage>3</lpage>.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Khullar</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>G</given-names></name><name name-style="western"><surname>Mastana</surname><given-names>S</given-names></name></person-group>. <article-title>Diabetes to cardiovascular disease: is depression the potential missing link?</article-title><source><italic toggle="yes">Med Hypotheses.</italic></source> (<year>2015</year>) <volume>84</volume>:<fpage>370</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2015.01.033</pub-id><pub-id pub-id-type="pmid">25655224</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Exton</surname><given-names>J</given-names></name></person-group>. <article-title>Signaling through phosphatidylcholine breakdown.</article-title><source><italic toggle="yes">J Biol Chem.</italic></source> (<year>1990</year>) <volume>265</volume>:<fpage>1</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">2104616</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>CM</given-names></name><name name-style="western"><surname>Breeze</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>SA</given-names></name><name name-style="western"><surname>Babb</surname><given-names>SM</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>BB</given-names></name><name name-style="western"><surname>Villafuerte</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex.</article-title><source><italic toggle="yes">Bipolar Disord.</italic></source> (<year>2000</year>) <volume>2(3 Pt. 2)</volume><fpage>207</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">11249799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1399-5618.2000.20302.x</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janowsky</surname><given-names>D</given-names></name><name name-style="western"><surname>el-Yousef</surname><given-names>M</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J</given-names></name><name name-style="western"><surname>Sekerke</surname><given-names>H</given-names></name></person-group>. <article-title>A cholinergic-adrenergic hypothesis of mania and depression.</article-title><source><italic toggle="yes">Lancet.</italic></source> (<year>1972</year>) <volume>2</volume>:<fpage>632</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(72)93021-8</pub-id><pub-id pub-id-type="pmid">4116781</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breisch</surname><given-names>J</given-names></name><name name-style="western"><surname>Averhoff</surname><given-names>B</given-names></name></person-group>. <article-title>Identification of osmo-dependent and osmo-independent betaine-choline-carnitine transporters in Acinetobacter baumannii: role in osmostress protection and metabolic adaptation.</article-title><source><italic toggle="yes">Environ Microbiol.</italic></source> (<year>2020</year>) <volume>22</volume><fpage>2724</fpage>&#8211;<lpage>2735</lpage>.<pub-id pub-id-type="pmid">32219961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1462-2920.14998</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MY</given-names></name><name name-style="western"><surname>Chan</surname><given-names>MH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HH</given-names></name></person-group>. <article-title>Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice.</article-title><source><italic toggle="yes">Psychopharmacology.</italic></source> (<year>2016</year>) <volume>233</volume><fpage>3223</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">27363702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-016-4359-x</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>K</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>A</given-names></name><name name-style="western"><surname>Cervenka</surname><given-names>E</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Guadagno</surname><given-names>E</given-names></name><name name-style="western"><surname>Trakadis</surname><given-names>Y</given-names></name></person-group>. <article-title>Biomarkers for major depressive and bipolar disorders using metabolomics: a systematic review.</article-title><source><italic toggle="yes">Am J Med Genet.</italic></source> (<year>2019</year>) <volume>180</volume>:<fpage>122</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.32680</pub-id><pub-id pub-id-type="pmid">30411484</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#322;adna</surname><given-names>A</given-names></name><name name-style="western"><surname>Marchlewicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Piechowska</surname><given-names>T</given-names></name><name name-style="western"><surname>Kruk</surname><given-names>I</given-names></name><name name-style="western"><surname>Aboul-Enein</surname><given-names>H</given-names></name></person-group>. <article-title>Reactivity of pyruvic acid and its derivatives towards reactive oxygen species.</article-title><source><italic toggle="yes">Luminescence.</italic></source> (<year>2015</year>) <volume>30</volume>:<fpage>1153</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/bio.2879</pub-id><pub-id pub-id-type="pmid">25754627</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Setoyama</surname><given-names>D</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>R</given-names></name><name name-style="western"><surname>Kunugi</surname><given-names>H</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-A multicenter pilot analysis.</article-title><source><italic toggle="yes">PLoS One.</italic></source> (<year>2016</year>) <volume>11</volume>:<issue>e0165267</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0165267</pub-id><pub-id pub-id-type="pmid">27984586</pub-id><pub-id pub-id-type="pmcid">PMC5161310</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>M</given-names></name></person-group>. <article-title>A focused review of the role of ketone bodies in health and disease.</article-title><source><italic toggle="yes">J Med Food.</italic></source> (<year>2013</year>) <volume>16</volume>:<fpage>965</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/jmf.2012.2592</pub-id><pub-id pub-id-type="pmid">24138078</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sada</surname><given-names>N</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Katsu</surname><given-names>T</given-names></name><name name-style="western"><surname>Otsuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T</given-names></name></person-group>. <article-title>Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy.</article-title><source><italic toggle="yes">Science.</italic></source> (<year>2015</year>) <volume>347</volume>:<fpage>1362</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa1299</pub-id><pub-id pub-id-type="pmid">25792327</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name></person-group>. <article-title>Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: a <sup>1</sup>H magnetic resonance spectroscopy study.</article-title><source><italic toggle="yes">Psychiatry Clin Neurosci.</italic></source> (<year>2014</year>) <volume>68</volume>:<fpage>357</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1111/pcn.12138</pub-id><pub-id pub-id-type="pmid">24393367</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tallan</surname><given-names>H</given-names></name><name name-style="western"><surname>Moore</surname><given-names>S</given-names></name><name name-style="western"><surname>Stein</surname><given-names>W</given-names></name></person-group>. <article-title>N-Acetyl-L-aspartic acid in brain.</article-title><source><italic toggle="yes">J Biol Chem.</italic></source> (<year>1956</year>) <volume>219</volume>:<fpage>257</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">13295277</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moffett</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ross</surname><given-names>B</given-names></name><name name-style="western"><surname>Arun</surname><given-names>P</given-names></name><name name-style="western"><surname>Madhavarao</surname><given-names>CN</given-names></name><name name-style="western"><surname>Namboodiri</surname><given-names>AM</given-names></name></person-group>. <article-title>N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.</article-title><source><italic toggle="yes">Prog Neurobiol.</italic></source> (<year>2007</year>). <volume>81</volume>:<fpage>89</fpage>&#8211;<lpage>131</lpage>.<pub-id pub-id-type="pmid">17275978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2006.12.003</pub-id><pub-id pub-id-type="pmcid">PMC1919520</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M</given-names></name><name name-style="western"><surname>Verkerk</surname><given-names>R</given-names></name><name name-style="western"><surname>Vandoolaeghe</surname><given-names>E</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><name name-style="western"><surname>Scharp&#233;</surname><given-names>S</given-names></name></person-group>. <article-title>Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.</article-title><source><italic toggle="yes">Acta Psychiatr Scand.</italic></source> (<year>1998</year>) <volume>97</volume>:<fpage>302</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0447.1998.tb10004.x</pub-id><pub-id pub-id-type="pmid">9570492</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bao</surname><given-names>S</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><etal/></person-group><article-title>Metabolic profiling in bipolar disorder patients during depressive episodes.</article-title><source><italic toggle="yes">Front Psychiatry.</italic></source> (<year>2020</year>) <volume>11</volume>:<issue>569612</issue>. <pub-id pub-id-type="doi">10.3389/fpsyt.2020.569612</pub-id><pub-id pub-id-type="pmid">33391044</pub-id><pub-id pub-id-type="pmcid">PMC7772141</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meunier</surname><given-names>C</given-names></name><name name-style="western"><surname>Dall&#233;rac</surname><given-names>G</given-names></name><name name-style="western"><surname>Le Roux</surname><given-names>N</given-names></name><name name-style="western"><surname>Sacchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Levasseur</surname><given-names>G</given-names></name><name name-style="western"><surname>Amar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serine and glycine differentially control neurotransmission during visual cortex critical period.</article-title><source><italic toggle="yes">PLoS One.</italic></source> (<year>2016</year>) <volume>11</volume>:<issue>e0151233</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0151233</pub-id><pub-id pub-id-type="pmid">27003418</pub-id><pub-id pub-id-type="pmcid">PMC4803205</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peyrovian</surname><given-names>B</given-names></name><name name-style="western"><surname>Rosenblat</surname><given-names>J</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Iacobucci</surname><given-names>M</given-names></name><name name-style="western"><surname>Brietzke</surname><given-names>E</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>R</given-names></name></person-group>. <article-title>The glycine site of NMDA receptors: a target for cognitive enhancement in psychiatric disorders.</article-title><source><italic toggle="yes">Prog Neuropsychopharmacol Biol Psychiatry.</italic></source> (<year>2019</year>) <volume>92</volume>:<fpage>387</fpage>&#8211;<lpage>404</lpage>.<pub-id pub-id-type="pmid">30738126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pnpbp.2019.02.001</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fossat</surname><given-names>P</given-names></name><name name-style="western"><surname>Turpin</surname><given-names>FR</given-names></name><name name-style="western"><surname>Sacchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Dulong</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>T</given-names></name><name name-style="western"><surname>Rivet</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex.</article-title><source><italic toggle="yes">Cereb Cortex.</italic></source> (<year>2012</year>). <volume>22</volume><fpage>595</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="pmid">21690263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhr130</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curcio</surname><given-names>L</given-names></name><name name-style="western"><surname>Podda</surname><given-names>MV</given-names></name><name name-style="western"><surname>Leone</surname><given-names>L</given-names></name><name name-style="western"><surname>Piacentini</surname><given-names>R</given-names></name><name name-style="western"><surname>Mastrodonato</surname><given-names>A</given-names></name><name name-style="western"><surname>Cappelletti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Reduced D-serine levels in the nucleus accumbens of cocaine-treated rats hinder.</article-title><source><italic toggle="yes">Brain.</italic></source> (<year>2013</year>). <volume>136(Pt. 4)</volume>:<fpage>1216</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">23518710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awt036</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castanheira</surname><given-names>L</given-names></name><name name-style="western"><surname>Silva</surname><given-names>C</given-names></name><name name-style="western"><surname>Cheniaux</surname><given-names>E</given-names></name><name name-style="western"><surname>Telles-Correia</surname><given-names>D</given-names></name></person-group>. <article-title>Neuroimaging correlates of depression-implications to clinical practice.</article-title><source><italic toggle="yes">Front Psychiatry.</italic></source> (<year>2019</year>) <volume>10</volume>:<issue>703</issue>. <pub-id pub-id-type="doi">10.3389/fpsyt.2019.00703</pub-id><pub-id pub-id-type="pmid">31632306</pub-id><pub-id pub-id-type="pmcid">PMC6779851</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>